{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T20:20:03Z","timestamp":1793132403492,"version":"4.5.0"},"reference-count":182,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.bcp.2019.05.030","type":"journal-article","created":{"date-parts":[[2019,6,4]],"date-time":"2019-06-04T12:25:39Z","timestamp":1559651139000},"page":"300-312","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":89,"special_numbering":"C","title":["Nitric oxide-enhancing or -releasing agents as antithrombotic drugs"],"prefix":"10.1016","volume":"166","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5365-8445","authenticated-orcid":false,"given":"P.","family":"Gresele","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Momi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Guglielmini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2019.05.030_b0005","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1073\/pnas.87.2.682","article-title":"Isolation of nitric oxide synthetase, a calmodulin-requiring enzyme","volume":"87","author":"Bredt","year":"1990","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.bcp.2019.05.030_b0010","doi-asserted-by":"crossref","first-page":"7773","DOI":"10.1073\/pnas.88.17.7773","article-title":"Purification and characterization of the cytokine-induced macrophage nitric oxide synthase: a FAD-and FMN-containing flavoprotein (L-arginine\/endothelium-derived relaxing factor\/interferon y)","volume":"88","author":"Stuehr","year":"1991","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bcp.2019.05.030_b0015","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1006\/abbi.1994.1454","article-title":"The inhibition of the constitutive bovine endothelial nitric oxide synthase by imidazole and indazole agents","volume":"314","author":"Wolff","year":"1994","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.bcp.2019.05.030_b0020","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1093\/eurheartj\/ehr304","article-title":"Nitric oxide synthases: regulation and function","volume":"33","author":"F\u00f6rstermann","year":"2012","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.bcp.2019.05.030_b0025","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1042\/CS20070108","article-title":"Mechanisms for the role of tetrahydrobiopterin in endothelial function and vascular disease","volume":"113","author":"Schmidt","year":"2007","journal-title":"Clin. Sci."},{"issue":"7","key":"10.1016\/j.bcp.2019.05.030_b0030","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1096\/fj.06-7434com","article-title":"Alternative splicing in intron 13 of the human eNOS gene: a potential mechanism for regulating eNOS activity","volume":"21","author":"Lorenz","year":"2007","journal-title":"FASEB J."},{"issue":"4","key":"10.1016\/j.bcp.2019.05.030_b0035","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.bbrc.2010.02.045","article-title":"MiR21 is induced in endothelial cells by shear stress and modulates apoptosis and eNOS activity","volume":"393","author":"Weber","year":"2010","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"6","key":"10.1016\/j.bcp.2019.05.030_b0040","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1161\/HYPERTENSIONAHA.112.197301","article-title":"Essential role of microRNA-155 in regulating endothelium-dependent vasorelaxation by targeting endothelial nitric oxide synthase","volume":"60","author":"Sun","year":"2012","journal-title":"Hypertension"},{"issue":"8","key":"10.1016\/j.bcp.2019.05.030_b0045","doi-asserted-by":"crossref","first-page":"841","DOI":"10.3109\/10715762.2014.929122","article-title":"LOX-1 and ROS, inseparable factors in the process of endothelial damage","volume":"48","author":"Lubrano","year":"2014","journal-title":"Free Radic. Res."},{"issue":"Pt 1","key":"10.1016\/j.bcp.2019.05.030_b0050","first-page":"1","article-title":"Arginine metabolism: nitric oxide and beyond","volume":"336","author":"Wu","year":"1998","journal-title":"Biochem. J."},{"key":"10.1016\/j.bcp.2019.05.030_b0055","first-page":"H342","article-title":"Arginase modulates nitric oxide production in activated macrophages","volume":"274","author":"Chang","year":"1998","journal-title":"Am. J. Physiol."},{"issue":"1","key":"10.1016\/j.bcp.2019.05.030_b0060","first-page":"E75","article-title":"Regulatory role of arginase I and II in nitric oxide, polyamine, and proline syntheses in endothelial cells","volume":"280","author":"Li","year":"2001","journal-title":"Am. J. Physiol. Metab."},{"issue":"5","key":"10.1016\/j.bcp.2019.05.030_b0065","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/j.1600-0609.1997.tb01676.x","article-title":"Evidence for a NO synthase in porcine platelets which is stimulated during activation\/aggregation","volume":"58","author":"Berkels","year":"2009","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.bcp.2019.05.030_b0070","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1016\/0024-3205(95)02191-K","article-title":"Expression of constitutive endothelial nitric oxide synthase in human blood platelets","volume":"57","author":"Sase","year":"1995","journal-title":"Life Sci."},{"issue":"20","key":"10.1016\/j.bcp.2019.05.030_b0075","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1182\/blood-2012-07-442277","article-title":"Human red blood cells at work: identification and visualization of erythrocytic eNOS activity in health and disease","volume":"120","author":"Cortese-Krott","year":"2012","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.bcp.2019.05.030_b0080","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1016\/j.bbamcr.2011.06.008","article-title":"Molecular and biochemical characterization of nitric oxide synthase isoforms and their intracellular distribution in human peripheral blood mononuclear cells","volume":"1813","author":"Saluja","year":"2011","journal-title":"Biochim. Biophys. Acta. Mol. Cell Res."},{"issue":"1","key":"10.1016\/j.bcp.2019.05.030_b0085","first-page":"65","article-title":"Nitric oxide and its antithrombotic action in the cardiovascular system","volume":"5","author":"Reichanbach","year":"2005","journal-title":"Curr. Drug Target. Cardiovasc. Hematol. Disord."},{"issue":"1","key":"10.1016\/j.bcp.2019.05.030_b0090","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1160\/TH09-08-0562","article-title":"Endothelium, venous thromboembolism and ischaemic cardiovascular events","volume":"103","author":"Gresele","year":"2010","journal-title":"Thromb. Haemost."},{"issue":"3","key":"10.1016\/j.bcp.2019.05.030_b0095","first-page":"183","article-title":"Endothelial dysfunction: cardiovascular risk factors, therapy, and outcome","volume":"1","author":"Hadi","year":"2005","journal-title":"Vasc. Health Risk Manag."},{"issue":"8","key":"10.1016\/j.bcp.2019.05.030_b0100","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/nrd2222","article-title":"Peroxynitrite: biochemistry, pathophysiology and development of therapeutics","volume":"6","author":"Szab\u00f3","year":"2007","journal-title":"Nat. Rev. Drug Discov."},{"issue":"2","key":"10.1016\/j.bcp.2019.05.030_b0105","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1161\/01.ATV.0000253884.13901.e4","article-title":"Implications of early structural-functional changes in the endothelium for vascular disease","volume":"27","author":"Simionescu","year":"2007","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"4","key":"10.1016\/j.bcp.2019.05.030_b0110","first-page":"190","article-title":"Expression of nitric oxide synthase in human peripheral blood mononuclear cells and neutrophils","volume":"47","author":"Amin","year":"1995","journal-title":"J. Inflamm."},{"issue":"10","key":"10.1016\/j.bcp.2019.05.030_b0115","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1038\/ni1001-907","article-title":"Nitric oxide and the immune response","volume":"2","author":"Bogdan","year":"2001","journal-title":"Nat. Immunol."},{"issue":"4\u20135","key":"10.1016\/j.bcp.2019.05.030_b0120","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/S0891-5849(98)00094-X","article-title":"Modulation of leukocyte-endothelial interactions by reactive metabolites of oxygen and nitrogen: relevance to ischemic heart disease","volume":"25","author":"Grisham","year":"1998","journal-title":"Free Radic. Biol. Med."},{"issue":"40","key":"10.1016\/j.bcp.2019.05.030_b0125","doi-asserted-by":"crossref","first-page":"27540","DOI":"10.1074\/jbc.M114.604231","article-title":"Inflammatory monocytes determine endothelial nitric-oxide synthase uncoupling and nitro-oxidative stress induced by Angiotensin II","volume":"289","author":"Kossmann","year":"2014","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.bcp.2019.05.030_b0130","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/S0008-6363(99)00148-0","article-title":"Inducible nitric oxide synthase colocalizes with signs of lipid oxidation\/peroxidation in human atherosclerotic plaques","volume":"43","author":"Cromheeke","year":"1999","journal-title":"Cardiovasc. Res."},{"issue":"8","key":"10.1016\/j.bcp.2019.05.030_b0135","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1161\/ATVBAHA.112.301068","article-title":"Circulating blood endothelial nitric oxide synthase contributes to the regulation of systemic blood pressure and nitrite homeostasis","volume":"33","author":"Wood","year":"2013","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"1","key":"10.1016\/j.bcp.2019.05.030_b0140","first-page":"1","article-title":"Depletion of circulating blood NOS3 increases severity of myocardial infarction and left ventricular dysfunction","volume":"109","author":"Merx","year":"2013","journal-title":"Basic Res. Cardiol."},{"issue":"8","key":"10.1016\/j.bcp.2019.05.030_b0145","article-title":"Nitric oxide synthetic pathway in red blood cells is impaired in coronary artery disease","volume":"8","author":"Veglia","year":"2013","journal-title":"PLoS One"},{"issue":"13","key":"10.1016\/j.bcp.2019.05.030_b0150","doi-asserted-by":"crossref","first-page":"5193","DOI":"10.1073\/pnas.87.13.5193","article-title":"An L-arginine\/nitric oxide pathway present in human platelets regulates aggregation","volume":"87","author":"Radomski","year":"1990","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"2","key":"10.1016\/j.bcp.2019.05.030_b0155","first-page":"350","article-title":"Nitric oxide released from activated platelets inhibits platelet recruitment","volume":"100","author":"Alpert","year":"2008","journal-title":"J. Clin. Invest."},{"issue":"2\u20133","key":"10.1016\/j.bcp.2019.05.030_b0160","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/S0304-4165(99)00202-0","article-title":"Platelet aggregation may not be a prerequisite for collagen-stimulated platelet generation of nitric oxide","volume":"1473","author":"Smith","year":"1999","journal-title":"Biochim. Biophys. Acta"},{"issue":"2","key":"10.1016\/j.bcp.2019.05.030_b0165","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/ki.1993.264","article-title":"Enhanced nitric oxide synthesis in uremia: implications for platelet dysfunction and dialysis hypotension","volume":"44","author":"Noris","year":"1993","journal-title":"Kidney Int."},{"issue":"2","key":"10.1016\/j.bcp.2019.05.030_b0170","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1006\/bbrc.1993.1914","article-title":"Direct electrochemical measurement of nitric oxide released from human platelets","volume":"194","author":"Malinski","year":"1993","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"4","key":"10.1016\/j.bcp.2019.05.030_b0175","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1182\/blood-2014-06-579474","article-title":"Visualization of nitric oxide production by individual platelets during adhesion in flowing blood","volume":"125","author":"Cozzi","year":"2015","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.bcp.2019.05.030_b0180","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1007\/s00726-015-1986-1","article-title":"A review and discussion of platelet nitric oxide and nitric oxide synthase: do blood platelets produce nitric oxide from l-arginine or nitrite?","volume":"47","author":"Gambaryan","year":"2015","journal-title":"Amino Acids."},{"issue":"6","key":"10.1016\/j.bcp.2019.05.030_b0185","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1160\/TH03-09-0588","article-title":"Endothelial nitric oxide synthase plays a minor role in inhibition of arterial thrombus formation","volume":"93","author":"\u00d6z\u00fcyaman","year":"2005","journal-title":"Thromb. Haemost."},{"issue":"1","key":"10.1016\/j.bcp.2019.05.030_b0190","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/00005344-199601000-00024","article-title":"Further evidence of the presence of constitutive and inducible nitric oxide synthase isoforms in human platelets","volume":"27","author":"Chen","year":"1996","journal-title":"J. Cardiovasc. Pharmacol."},{"issue":"1","key":"10.1016\/j.bcp.2019.05.030_b0195","doi-asserted-by":"crossref","first-page":"H220","DOI":"10.1152\/ajpheart.00950.2001","article-title":"Ovariectomy upregulates expression of estrogen receptors, NOS, and HSPs in porcine platelets","volume":"283","author":"Jayachandran","year":"2002","journal-title":"Am. J. Physiol. Circ. Physiol."},{"issue":"2","key":"10.1016\/j.bcp.2019.05.030_b0200","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1159\/000145327","article-title":"Statin potentiates human platelet eNOS activity without enhancing eNOS mRNA and protein levels","volume":"26","author":"Yemisci","year":"2008","journal-title":"Cerebrovasc. Dis."},{"key":"10.1016\/j.bcp.2019.05.030_b0205","article-title":"Blood platelets have nitric oxide synthase","volume":"28","author":"Momi","year":"2015","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"14","key":"10.1016\/j.bcp.2019.05.030_b0210","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1093\/cvr\/cvx179","article-title":"Differential eNOS-signalling by platelet subpopulations regulates adhesion and aggregation","volume":"113","author":"Radziwon-Balicka","year":"2017","journal-title":"Cardiovasc. Res."},{"issue":"4","key":"10.1016\/j.bcp.2019.05.030_b0215","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1161\/ATVBAHA.114.303290","article-title":"Stimulation of platelet nitric oxide production by nebivolol prevents thrombosis","volume":"34","author":"Momi","year":"2014","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"12","key":"10.1016\/j.bcp.2019.05.030_b0220","first-page":"1416","article-title":"Deficient platelet-derived nitric oxide and enhanced hemostasis in mice lacking the NOSIII gene","volume":"84","author":"Loscalzo","year":"2012","journal-title":"Circ. Res."},{"issue":"15","key":"10.1016\/j.bcp.2019.05.030_b0225","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1161\/01.CIR.98.15.1481","article-title":"Impaired platelet production of nitric oxide predicts presence of acute coronary syndromes","volume":"98","author":"Freedman","year":"1998","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.bcp.2019.05.030_b0230","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1161\/01.ATV.0000193622.77294.57","article-title":"Platelet nitric oxide responsiveness","volume":"25","author":"Willoughby","year":"2005","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"3","key":"10.1016\/j.bcp.2019.05.030_b0235","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s10557-008-6098-7","article-title":"Platelet hyperaggregability: Impaired responsiveness to nitric oxide (\u201cplatelet NO resistance\u201d) as a therapeutic target","volume":"22","author":"Rajendran","year":"2008","journal-title":"Cardiovasc. Drugs Ther."},{"issue":"2","key":"10.1016\/j.bcp.2019.05.030_b0240","first-page":"349","article-title":"In vivo platelet activation and platelet hyperreactivity in abacavir-treated HIV-infected patients","volume":"110","author":"Falcinelli","year":"2013","journal-title":"Thromb. Haemost."},{"issue":"4","key":"10.1016\/j.bcp.2019.05.030_b0245","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1161\/01.HYP.35.4.904","article-title":"Platelet-derived nitric oxide and coronary risk factors","volume":"35","author":"Ikeda","year":"2000","journal-title":"Hypertension"},{"issue":"6546","key":"10.1016\/j.bcp.2019.05.030_b0250","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/377239a0","article-title":"Hypertension in mice lacking the gene for endothelial nitric oxide synthase","volume":"377","author":"Huang","year":"1995","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.bcp.2019.05.030_b0255","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1161\/01.CIR.89.5.2035","article-title":"Nitric oxide regulates basal systemic and pulmonary vascular resistance in healthy humans","volume":"89","author":"Stamler","year":"2012","journal-title":"Circulation"},{"issue":"22","key":"10.1016\/j.bcp.2019.05.030_b0260","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1056\/NEJM199005313222201","article-title":"Platelet hyperreactivity and prognosis in survivors of myocardial infarction","volume":"322","author":"Trip","year":"1990","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.bcp.2019.05.030_b0265","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1161\/01.CIR.0000141575.92958.9C","article-title":"Platelet function predicts myocardial damage in patients with acute myocardial infarction","volume":"110","author":"Frossard","year":"2004","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.bcp.2019.05.030_b0270","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1172\/JCI118522","article-title":"Decreased platelet inhibition by nitric oxide in two brothers with a history of arterial thrombosis","volume":"97","author":"Freedman","year":"1996","journal-title":"J. Clin. Invest."},{"issue":"7480","key":"10.1016\/j.bcp.2019.05.030_b0275","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/nature12722","article-title":"Dysfunctional nitric oxide signalling increases risk of myocardial infarction","volume":"504","author":"Erdmann","year":"2013","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.bcp.2019.05.030_b0280","doi-asserted-by":"crossref","first-page":"3191","DOI":"10.1161\/01.ATV.17.11.3191","article-title":"Plasma Levels of nitrite\/nitrate and platelet cGMP levels are decreased in patients with atrial fibrillation","volume":"17","author":"Minamino","year":"1997","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"7","key":"10.1016\/j.bcp.2019.05.030_b0285","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1161\/01.STR.31.7.1634","article-title":"Association between the Glu298Asp polymorphism in the endothelial constitutive nitric oxide synthase gene and brain infarction","volume":"31","author":"Elbaz","year":"2000","journal-title":"Stroke"},{"issue":"4","key":"10.1016\/j.bcp.2019.05.030_b0290","first-page":"238","article-title":"Association of the missense Glu298Asp variant of the endothelial nitric oxide synthase gene with severe preeclampsia","volume":"7","author":"Yoshimura","year":"2000","journal-title":"J. Soc. Gynecol. Investig."},{"issue":"6","key":"10.1016\/j.bcp.2019.05.030_b0295","doi-asserted-by":"crossref","first-page":"812","DOI":"10.3324\/haematol.10872","article-title":"Endothelial dysfunction in patients with spontaneous venous thromboembolism","volume":"92","author":"Migliacci","year":"2007","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.bcp.2019.05.030_b0300","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1253\/circj.CJ-13-1325","article-title":"Utility of noninvasive endothelial function test for prediction of deep vein thrombosis after total hip or knee arthroplasty","volume":"78","author":"Suzuki","year":"2014","journal-title":"Circ. J."},{"issue":"4","key":"10.1016\/j.bcp.2019.05.030_b0305","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1172\/JCI1699","article-title":"Direct evidence for the importance of endothelium-derived nitric oxide in vascular remodeling","volume":"101","author":"Rudic","year":"1998","journal-title":"J. Clin. Invest."},{"issue":"14","key":"10.1016\/j.bcp.2019.05.030_b0310","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1096\/fj.02-0155fje","article-title":"Vasculoprotective roles of neuronal nitric oxide synthase","volume":"16","author":"Morishita","year":"2002","journal-title":"FASEB J."},{"issue":"4","key":"10.1016\/j.bcp.2019.05.030_b0315","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1161\/hc2901.091399","article-title":"Accelerated atherosclerosis, aortic aneurysm formation, and ischemic heart disease in apolipoprotein E\/endothelial nitric oxide synthase double-knockout mice","volume":"104","author":"Kuhlencordt","year":"2001","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.bcp.2019.05.030_b0320","first-page":"77","article-title":"Inducible nitric oxide synthase is present within human atherosclerotic lesions and promotes the formation and activity of peroxynitrite","volume":"75","author":"Buttery","year":"1996","journal-title":"Lab. Invest."},{"issue":"1","key":"10.1016\/j.bcp.2019.05.030_b0325","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0021-9150(00)00636-5","article-title":"Mice lacking inducible nitric oxide synthase develop spontaneous hypercholesterolaemia and aortic atheromas","volume":"156","author":"Ihrig","year":"2001","journal-title":"Atherosclerosis"},{"issue":"4","key":"10.1016\/j.bcp.2019.05.030_b0330","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1161\/CIRCRESAHA.115.306301","article-title":"Endothelial cell dysfunction and the pathobiology of atherosclerosis","volume":"118","author":"Gimbrone","year":"2016","journal-title":"Circ. Res."},{"key":"10.1016\/j.bcp.2019.05.030_b0335","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/jsfa.2351","article-title":"Nitrate in vegetables: toxicity, content, intake and EC regulation","volume":"86","author":"Santamaria","year":"2006","journal-title":"J. Sci. Food Agric."},{"issue":"2","key":"10.1016\/j.bcp.2019.05.030_b0340","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/nrd2466","article-title":"The nitrate-nitrite-nitric oxide pathway in physiology and therapeutics","volume":"7","author":"Lundberg","year":"2008","journal-title":"Nat. Rev. Drug Discov."},{"issue":"11","key":"10.1016\/j.bcp.2019.05.030_b0345","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1055\/s-0030-1250737","article-title":"Vascular protection by natural product-derived polyphenols: in vitro and in vivo evidence","volume":"77","author":"Schini-Kerth","year":"2011","journal-title":"Planta Med."},{"issue":"11","key":"10.1016\/j.bcp.2019.05.030_b0350","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.3390\/nu9111270","article-title":"Acute effects of nitrate-rich beetroot juice on blood pressure, hemostasis and vascular inflammation markers in healthy older adults: a randomized, placebo-controlled crossover study","volume":"9","author":"Raubenheimer","year":"2017","journal-title":"Nutrients"},{"issue":"8S Suppl","key":"10.1016\/j.bcp.2019.05.030_b0355","doi-asserted-by":"crossref","first-page":"2073S","DOI":"10.1093\/jn\/130.8.2073S","article-title":"Dietary intake and bioavailability of polyphenols","volume":"130","author":"Scalbert","year":"2000","journal-title":"J. Nutr."},{"issue":"3","key":"10.1016\/j.bcp.2019.05.030_b0360","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.jnutbio.2010.07.004","article-title":"Effects of resveratrol and other wine polyphenols on vascular function: an update","volume":"22","author":"Gresele","year":"2011","journal-title":"J. Nutr. Biochem."},{"issue":"23","key":"10.1016\/j.bcp.2019.05.030_b0365","doi-asserted-by":"crossref","first-page":"2792","DOI":"10.1161\/01.CIR.103.23.2792","article-title":"Select flavonoids and whole juice from purple grapes inhibit platelet function and enhance nitric oxide release","volume":"103","author":"Freedman","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.bcp.2019.05.030_b0370","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.niox.2013.04.001","article-title":"Role of SIRT1 and FOXO factors in eNOS transcriptional activation by resveratrol","volume":"32","author":"Xia","year":"2013","journal-title":"Nitric Oxide"},{"issue":"1","key":"10.1016\/j.bcp.2019.05.030_b0375","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1124\/jpet.110.168724","article-title":"Resveratrol reverses endothelial nitric-oxide synthase uncoupling in apolipoprotein E knockout mice","volume":"335","author":"Xia","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bcp.2019.05.030_b0380","doi-asserted-by":"crossref","first-page":"7460","DOI":"10.1074\/jbc.M411565200","article-title":"Resveratrol and estradiol rapidly activate MAPK signaling through estrogen receptors \u03b1 and \u03b2 in endothelial cells","volume":"280","author":"Klinge","year":"2005","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.bcp.2019.05.030_b0385","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/sj.bjp.0702749","article-title":"Trans-resveratrol inhibits calcium influx in thrombin-stimulated human platelets","volume":"128","author":"Dobrydneva","year":"1999","journal-title":"Br. J. Pharmacol."},{"issue":"3\u20134","key":"10.1016\/j.bcp.2019.05.030_b0390","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0049-3848(02)00273-6","article-title":"Effect of resveratrol, a natural polyphenolic compound, on platelet activation induced by endotoxin or thrombin","volume":"107","author":"Olas","year":"2002","journal-title":"Thromb. Res."},{"issue":"9","key":"10.1016\/j.bcp.2019.05.030_b0395","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1093\/jn\/138.9.1602","article-title":"Resveratrol, at concentrations attainable with moderate wine consumption, stimulates human platelet nitric oxide production","volume":"138","author":"Gresele","year":"2008","journal-title":"J. Nutr."},{"key":"10.1016\/j.bcp.2019.05.030_b0400","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.fitote.2015.07.009","article-title":"Effect of substituted stilbenes on platelet function","volume":"105","author":"Messina","year":"2015","journal-title":"Fitoterapia"},{"issue":"12","key":"10.1016\/j.bcp.2019.05.030_b0405","first-page":"229","article-title":"Comparison of endothelial pleiotropic actions of angiotensin converting enzyme inhibitors and statins","volume":"947","author":"Gryglewski","year":"2006","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"2","key":"10.1016\/j.bcp.2019.05.030_b0410","first-page":"231","article-title":"Antithrombotic effect of tissue and plasma type angiotensin converting enzyme inhibitors in experimental thrombosis in rats","volume":"57","author":"Wojew\u00f3dzka-Zelezniakowicz","year":"2006","journal-title":"J. Physiol. Pharmacol."},{"issue":"4","key":"10.1016\/j.bcp.2019.05.030_b0415","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1007\/s00392-006-0363-1","article-title":"Differential antiplatelet effects of angiotensin converting enzyme inhibitors","volume":"95","author":"Skowasch","year":"2006","journal-title":"Clin. Res. Cardiol."},{"issue":"2","key":"10.1016\/j.bcp.2019.05.030_b0420","doi-asserted-by":"crossref","first-page":"96","DOI":"10.5414\/CP202503","article-title":"Evaluation of the effect of angiotensin converting enzyme inhibitors and angiotensin receptors blockers on aspirin antiplatelet effect","volume":"54","author":"Al-Azzam","year":"2016","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"issue":"1\u20132","key":"10.1016\/j.bcp.2019.05.030_b0425","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.cellimm.2013.08.003","article-title":"TLR4-mediated anti-atherosclerosis mechanisms of angiotensin-converting enzyme inhibitor \u2013 fosinopril","volume":"285","author":"Yang","year":"2013","journal-title":"Cell. Immunol."},{"issue":"12","key":"10.1016\/j.bcp.2019.05.030_b0430","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1016\/S0002-9149(97)00750-9","article-title":"Effects of quinapril on coronary blood flow in coronary artery disease patients with endothelial dysfunction","volume":"80","author":"Schlaifer","year":"1997","journal-title":"Am. J. Cardiol."},{"issue":"6","key":"10.1016\/j.bcp.2019.05.030_b0435","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1161\/01.CIR.95.6.1532","article-title":"Angiotensin-converting enzyme inhibition prevents arterial nuclear factor-kappa B activation, monocyte chemoattractant protein-1 expression, and macrophage infiltration in a rabbit model of early accelerated atherosclerosis","volume":"95","author":"Hern\u00e1ndez-Presa","year":"1997","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.bcp.2019.05.030_b0440","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3390\/jcm6060061","article-title":"Renin Inhibition with aliskiren: a decade of clinical experience","volume":"6","author":"Pantzaris","year":"2017","journal-title":"J. Clin. Med."},{"issue":"12","key":"10.1016\/j.bcp.2019.05.030_b0445","doi-asserted-by":"crossref","first-page":"3806","DOI":"10.1093\/ndt\/gfn357","article-title":"Angiotensin II type 1 receptor blocker ameliorates uncoupled endothelial nitric oxide synthase in rats with experimental diabetic nephropathy","volume":"23","author":"Satoh","year":"2008","journal-title":"Nephrol. Dial. Transplant."},{"issue":"3","key":"10.1016\/j.bcp.2019.05.030_b0450","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1177\/1074248411425491","article-title":"Characterization of the in vivo antiplatelet activity of the antihypertensive agent losartan","volume":"17","author":"Murad","year":"2012","journal-title":"J. Cardiovasc. Pharmacol. Ther."},{"issue":"4","key":"10.1016\/j.bcp.2019.05.030_b0455","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1159\/000073659","article-title":"Vascular protective effects of dihydropyridine calcium antagonists","volume":"69","author":"Berkels","year":"2003","journal-title":"Pharmacology"},{"issue":"3","key":"10.1016\/j.bcp.2019.05.030_b0460","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1161\/01.CIR.101.3.311","article-title":"Nifedipine-induced coronary vasodilation in ischemic hearts is attributable to bradykinin- and NO-dependent mechanisms in dogs","volume":"101","author":"Kitakaze","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.bcp.2019.05.030_b0465","doi-asserted-by":"crossref","first-page":"24","DOI":"10.7603\/s40681-014-0024-z","article-title":"New mechanisms of antiplatelet activity of nifedipine, an L-type calcium channel blocker","volume":"4","author":"Chou","year":"2014","journal-title":"Biomedicine"},{"issue":"1","key":"10.1016\/j.bcp.2019.05.030_b0470","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3181\/00379727-183-42390","article-title":"Comparison of verapamil and nifedipine in thrombosis models","volume":"183","author":"Myers","year":"1986","journal-title":"Exp. Biol. Med."},{"issue":"Suppl 10","key":"10.1016\/j.bcp.2019.05.030_b0475","first-page":"s68","article-title":"Effects of nitrendipine and tiapamil on 45Ca 2+ influx and platelet aggregation","volume":"10","author":"Philipp","year":"1987","journal-title":"J. Cardiovasc. Pharmacol."},{"issue":"11","key":"10.1016\/j.bcp.2019.05.030_b0480","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s00228-002-0556-0","article-title":"Beyond lipid-lowering: effects of statins on endothelial nitric oxide","volume":"58","author":"Laufs","year":"2003","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"10","key":"10.1016\/j.bcp.2019.05.030_b0485","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1161\/01.STR.31.10.2442","article-title":"Atorvastatin upregulates type III nitric oxide synthase in thrombocytes, decreases platelet activation, and protects from cerebral ischemia in normocholesterolemic mice","volume":"31","author":"Laufs","year":"2000","journal-title":"Stroke"},{"issue":"1","key":"10.1016\/j.bcp.2019.05.030_b0490","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1161\/CIRCRESAHA.116.308537","article-title":"Pleiotropic effects of statins on the cardiovascular system","volume":"120","author":"Oesterle","year":"2017","journal-title":"Circ. Res."},{"issue":"5","key":"10.1016\/j.bcp.2019.05.030_b0495","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1055\/s-0037-1614841","article-title":"Atorvastatin increases ecNOS levels in human platelets of hyperlipidemic subjects","volume":"82","author":"Tannous","year":"1999","journal-title":"Thromb Haemost."},{"key":"10.1016\/j.bcp.2019.05.030_b0500","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00003495-198400282-00002","article-title":"\u03b1- and \u03b2-adrenergic receptor subtypes properties, distribution and regulation","volume":"28","author":"Molinoff","year":"1984","journal-title":"Drugs"},{"key":"10.1016\/j.bcp.2019.05.030_b0505","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1161\/01.CIR.0000139331.85766.AF","article-title":"Endothelial \u03b2 3 -adrenoceptors mediate vasorelaxation of human coronary microarteries through nitric oxide and endothelium-dependent hyperpolarization","volume":"110","author":"Dessy","year":"2004","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.bcp.2019.05.030_b0510","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/j.1527-3466.2008.00044.x","article-title":"Different pharmacological properties of two enantiomers in a unique \u03b2-blocker, nebivolol","volume":"26","author":"Ignarro","year":"2008","journal-title":"Cardiovasc. Ther."},{"issue":"7 Suppl. 1","key":"10.1016\/j.bcp.2019.05.030_b0515","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.amjmed.2010.04.012","article-title":"The role of nitric oxide in improving endothelial function and cardiovascular health: focus on nebivolol","volume":"123","author":"Bakris","year":"2010","journal-title":"Am. J. Med."},{"issue":"6","key":"10.1016\/j.bcp.2019.05.030_b0520","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1097\/00005344-200112000-00014","article-title":"Effects of nebivolol on human platelet aggregation","volume":"38","author":"Falciani","year":"2001","journal-title":"J. Cardiovasc. Pharmacol."},{"issue":"3","key":"10.1016\/j.bcp.2019.05.030_b0525","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1136\/hrt.2010.207365","article-title":"\u03b2-blockade with nebivolol for prevention of acute ischaemic events in elderly patients with heart failure","volume":"97","author":"Ambrosio","year":"2011","journal-title":"Heart"},{"issue":"3","key":"10.1016\/j.bcp.2019.05.030_b0530","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1006\/bbrc.2000.4177","article-title":"Up-Regulation of endothelial nitric oxide synthase through \u03b22-adrenergic receptor\u2014the role of a \u03b2-Blocker with NO-releasing action","volume":"280","author":"Jayachandran","year":"2001","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"4","key":"10.1016\/j.bcp.2019.05.030_b0535","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1111\/j.1365-2125.2011.04034.x","article-title":"Anti-platelet therapy: phosphodiesterase inhibitors","volume":"72","author":"Gresele","year":"2011","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.bcp.2019.05.030_b0540","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1055\/s-0038-1661437","article-title":"Mechanism of the antiplatelet action of dipyridamole in whole blood: modulation of adenosine concentration and activity","volume":"55","author":"Gresele","year":"1986","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.bcp.2019.05.030_b0545","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/0049-3848(90)90444-H","article-title":"Dipyridamole potentiates the anti-aggregating effect of endothelium-derived relaxing factor","volume":"57","author":"Sakuma","year":"1990","journal-title":"Thromb. Res."},{"issue":"2","key":"10.1016\/j.bcp.2019.05.030_b0550","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1006\/bbrc.1996.5998","article-title":"Inhibition of platelet adhesion to collagen by cGMP-elevating agents","volume":"231","author":"Wu","year":"1997","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"3","key":"10.1016\/j.bcp.2019.05.030_b0555","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1161\/01.STR.0000056527.34434.59","article-title":"Dipyridamole enhances NO\/cGMP-mediated vasodilator-stimulated phosphoprotein phosphorylation and signaling in human platelets","volume":"34","author":"Aktas","year":"2003","journal-title":"Stroke"},{"issue":"1","key":"10.1016\/j.bcp.2019.05.030_b0560","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1097\/00005344-199807000-00024","article-title":"Adenosine endogenously released during early reperfusion mitigates postischemic myocardial dysfunction by inhibiting platelet adhesion","volume":"32","author":"Seligmann","year":"1998","journal-title":"J. Cardiovasc. Pharmacol."},{"issue":"7","key":"10.1016\/j.bcp.2019.05.030_b0565","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1016\/S0735-1097(01)01270-0","article-title":"Cessation of platelet-mediated cyclic canine coronary occlusion after thrombolysis by combining nitric oxide inhalation with phosphodiesterase-5 inhibition","volume":"37","author":"Schmidt","year":"2001","journal-title":"J. Am. Coll. Cardiol."},{"issue":"2","key":"10.1016\/j.bcp.2019.05.030_b0570","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1080\/09537100500235966","article-title":"Effect of aspirin, clopidogrel and dipyridamole on soluble markers of vascular function in normal volunteers and patients with prior ischaemic stroke","volume":"17","author":"Zhao","year":"2006","journal-title":"Platelets"},{"issue":"3","key":"10.1016\/j.bcp.2019.05.030_b0575","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.thromres.2008.05.015","article-title":"Patients with primary antiphospholipid antibody syndrome and without associated vascular risk factors present a normal endothelial function","volume":"123","author":"Gresele","year":"2009","journal-title":"Thromb. Res."},{"issue":"1\u20132","key":"10.1016\/j.bcp.2019.05.030_b0580","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0014-2999(96)00551-1","article-title":"Effect of cilostazol, a cAMP phosphodiesterase inhibitor, on nitric oxide production by vascular smooth muscle cells","volume":"314","author":"Ikeda","year":"1996","journal-title":"Eur. J. Pharmacol."},{"issue":"4","key":"10.1016\/j.bcp.2019.05.030_b0585","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/ajh.2008.6","article-title":"Cilostazol activates AMP-activated protein kinase and restores endothelial function in diabetes","volume":"21","author":"Suzuki","year":"2008","journal-title":"Am. J. Hypertens."},{"issue":"1","key":"10.1016\/j.bcp.2019.05.030_b0590","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ejvs.2011.07.015","article-title":"Cilostazol stimulates revascularisation in response to Ischaemia via an eNOS-dependent mechanism","volume":"43","author":"Hori","year":"2012","journal-title":"Eur. J. Vasc. Endovasc. Surg."},{"issue":"6","key":"10.1016\/j.bcp.2019.05.030_b0595","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/j.1742-1241.2002.tb11296.x","article-title":"Pharmacology of phosphodiesterase-5 inhibitors","volume":"56","author":"Corbin","year":"2002","journal-title":"Int. J. Clin. Pract."},{"issue":"5A","key":"10.1016\/j.bcp.2019.05.030_b0600","doi-asserted-by":"crossref","first-page":"3C","DOI":"10.1016\/S0002-9149(99)00042-9","article-title":"Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro","volume":"83","author":"Wallis","year":"1999","journal-title":"Am. J. Cardiol."},{"issue":"4","key":"10.1016\/j.bcp.2019.05.030_b0605","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1097\/00005344-200104000-00008","article-title":"Modulation of human platelet aggregation by the phosphodiesterase type 5 inhibitor sildenafil","volume":"37","author":"Berkels","year":"2001","journal-title":"J. Cardiovasc. Pharmacol."},{"issue":"7","key":"10.1016\/j.bcp.2019.05.030_b0610","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1016\/S0735-1097(02)02139-3","article-title":"The effect of sildenafil on human vascular function, platelet activation, and myocardial ischemia","volume":"40","author":"Halcox","year":"2002","journal-title":"J. Am. Coll. Cardiol."},{"issue":"6","key":"10.1016\/j.bcp.2019.05.030_b0615","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1177\/0003319710362977","article-title":"Effects of tadalafil on platelets and endothelium in patients with erectile dysfunction and cardiovascular risk factors: a pilot study","volume":"61","author":"De Bon","year":"2010","journal-title":"Angiology"},{"key":"10.1016\/j.bcp.2019.05.030_b0620","doi-asserted-by":"crossref","first-page":"794","DOI":"10.4187\/respcare.03927","article-title":"Inhaled therapies for pulmonary hypertension","volume":"60","author":"Hill","year":"2015","journal-title":"Respir. Care"},{"issue":"1","key":"10.1016\/j.bcp.2019.05.030_b0625","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1097\/00000542-199507000-00007","article-title":"Inhibition of platelet aggregation by inhaled nitric oxide in patients with acute respiratory distress syndrome","volume":"83","author":"Samama","year":"1995","journal-title":"Anesthesiology"},{"issue":"29","key":"10.1016\/j.bcp.2019.05.030_b0630","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1093\/eurheartj\/ehy232","article-title":"Nitric oxide for inhalation in ST-elevation myocardial infarction (NOMI): a multicentre, double-blind, randomized controlled trial","volume":"39","author":"Janssens","year":"2018","journal-title":"Eur. Heart J."},{"issue":"3 Pt 1","key":"10.1016\/j.bcp.2019.05.030_b0635","doi-asserted-by":"crossref","first-page":"C701","DOI":"10.1152\/ajpcell.1992.262.3.C701","article-title":"Inhibition by sodium nitroprusside or PGE1 of tyrosine phosphorylation induced in platelets by thrombin or ADP","volume":"262","author":"Oda","year":"1992","journal-title":"Am. J. Physiol. Physiol."},{"issue":"1\u20132","key":"10.1016\/j.bcp.2019.05.030_b0640","first-page":"59","article-title":"Differential effects of sodium nitroprusside and hydralazine in a rat model of topical FeCl3-induced carotid artery thrombosis","volume":"111","author":"Welsh","year":"2003","journal-title":"Thromb. Res."},{"key":"10.1016\/j.bcp.2019.05.030_b0645","first-page":"272","article-title":"NO-releasing hybrids of cardiovascular drugs","volume":"vol. 5","author":"Martelli","year":"2011"},{"issue":"1","key":"10.1016\/j.bcp.2019.05.030_b0650","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.2042-7158.1998.tb03308.x","article-title":"inhibition of human platelet aggregation by diazeniumdiolates: extent of inhibition correlates with nitric oxide load delivered","volume":"50","author":"Raulli","year":"1998","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.bcp.2019.05.030_b0655","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ejphar.2014.04.027","article-title":"Specific inhibitory effects of the NO donor MAHMA\/NONOate on human platelets","volume":"735","author":"Kobsar","year":"2014","journal-title":"Eur. J. Pharmacol."},{"issue":"13","key":"10.1016\/j.bcp.2019.05.030_b0660","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1097\/00005537-200303000-00003","article-title":"Local administration of nitric oxide donor significantly impacts microvascular thrombosis","volume":"113","author":"Chiang","year":"2003","journal-title":"Laryngoscope"},{"issue":"6","key":"10.1016\/j.bcp.2019.05.030_b0665","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1016\/S0142-9612(01)00274-5","article-title":"Nitric oxide releasing silicone rubbers with improved blood compatibility: preparation, characterization, and in vivo evaluation","volume":"23","author":"Zhang","year":"2002","journal-title":"Biomaterials"},{"issue":"10","key":"10.1016\/j.bcp.2019.05.030_b0670","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1016\/j.biomaterials.2009.12.028","article-title":"The attenuation of platelet and monocyte activation in a rabbit model of extracorporeal circulation by a nitric oxide releasing polymer","volume":"31","author":"Major","year":"2010","journal-title":"Biomaterials"},{"issue":"1","key":"10.1016\/j.bcp.2019.05.030_b0675","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/0049-3848(88)90036-9","article-title":"Direct comparison of the effects of nitroprusside, SIN 1, and various nitrates on platelet aggregation and soluble guanylate cyclase activity","volume":"52","author":"Gerzer","year":"1988","journal-title":"Thromb. Res."},{"issue":"3","key":"10.1016\/j.bcp.2019.05.030_b0680","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.phrs.2011.03.014","article-title":"In vitro inhibition of human and rat platelets by NO donors, nitrosoglutathione, sodium nitroprusside and SIN-1, through activation of cGMP-independent pathways","volume":"64","author":"Priora","year":"2011","journal-title":"Pharmacol. Res."},{"issue":"2","key":"10.1016\/j.bcp.2019.05.030_b0685","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.atherosclerosis.2004.12.018","article-title":"Long-term treatment with the NO-donor molsidomine reduces circulating ICAM-1 levels in patients with stable angina","volume":"180","author":"Van Hove","year":"2005","journal-title":"Atherosclerosis"},{"issue":"1","key":"10.1016\/j.bcp.2019.05.030_b0690","doi-asserted-by":"crossref","first-page":"57","DOI":"10.2174\/1389557053402864","article-title":"Pharmacological properties of furoxans and benzofuroxans: recent developments","volume":"5","author":"Ceceretto","year":"2005","journal-title":"Mini-Reviews Med. Chem."},{"issue":"2","key":"10.1016\/j.bcp.2019.05.030_b0695","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/bjp.2008.263","article-title":"The enigma of nitroglycerin bioactivation and nitrate tolerance: news, views and troubles","volume":"155","author":"Mayer","year":"2008","journal-title":"Br. J. Pharmacol."},{"issue":"9","key":"10.1016\/j.bcp.2019.05.030_b0700","first-page":"561","article-title":"Platelet inhibitory effect of nitroglycerin in platelet-rich plasma: relevance of glutathione-s-transferases in plasma","volume":"44","author":"Chen","year":"1996","journal-title":"J. Investig. Med."},{"issue":"4 Pt 1","key":"10.1016\/j.bcp.2019.05.030_b0705","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/0002-8703(94)90538-X","article-title":"Nitroglycerin inhibits experimental thrombosis and reocclusion after thrombolysis","volume":"127","author":"Werns","year":"1994","journal-title":"Am. Heart J."},{"issue":"5","key":"10.1016\/j.bcp.2019.05.030_b0710","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1161\/01.CIR.95.5.1308","article-title":"Persistent inhibition of platelets during continuous nitroglycerin therapy despite hemodynamic tolerance","volume":"95","author":"Hebert","year":"1997","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.bcp.2019.05.030_b0715","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1136\/hrt.72.6.575","article-title":"Inhibition of platelet aggregation by transdermal glyceryl trinitrate","volume":"72","author":"Andrews","year":"1994","journal-title":"Heart"},{"issue":"7","key":"10.1016\/j.bcp.2019.05.030_b0720","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/0002-9149(90)91130-X","article-title":"Effects of nitroglycerin at therapeutic doses on platelet aggregation in unstable angina pectoris and acute myocardial infarction","volume":"66","author":"Diodati","year":"1990","journal-title":"Am. J. Cardiol."},{"issue":"3","key":"10.1016\/j.bcp.2019.05.030_b0725","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1016\/j.ijcard.2013.04.092","article-title":"Platelet inhibition by iv glyceryl trinitrate in patients with stable coronary artery disease on dual antiplatelet therapy subjected to PCI","volume":"168","author":"Davlouros","year":"2013","journal-title":"Int. J. Cardiol."},{"issue":"8594","key":"10.1016\/j.bcp.2019.05.030_b0730","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/S0140-6736(88)91906-X","article-title":"Effect of intravenous nitrates on mortality in acute myocardial infarction: an overview of the randomized trials","volume":"331","author":"Yusuf","year":"1988","journal-title":"Lancet"},{"issue":"1\u20132","key":"10.1016\/j.bcp.2019.05.030_b0735","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0009-8981(03)00046-9","article-title":"Nitric oxide and S-nitrosothiols in human blood","volume":"330","author":"Giustarini","year":"2003","journal-title":"Clin. Chim. Acta"},{"issue":"4","key":"10.1016\/j.bcp.2019.05.030_b0740","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1111\/j.1476-5381.1994.tb13192.x","article-title":"Comparative pharmacology of analogues of S-nitroso-N-acetyl-dl-penicillamine on human platelets","volume":"112","author":"Salas","year":"1994","journal-title":"Br. J. Pharmacol."},{"issue":"5","key":"10.1016\/j.bcp.2019.05.030_b0745","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1093\/cvr\/28.5.691","article-title":"Effects of S-nitroso-glutathione in the human forearm circulation: evidence for selective inhibition of platelet activation","volume":"28","author":"De Belder","year":"1994","journal-title":"Cardiovasc. Res."},{"issue":"1","key":"10.1016\/j.bcp.2019.05.030_b0750","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1161\/01.ATV.16.1.51","article-title":"Platelet activation in acute myocardial infarction and unstable angina is inhibited by nitric oxide donors","volume":"16","author":"Langford","year":"1996","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"4","key":"10.1016\/j.bcp.2019.05.030_b0755","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1093\/oxfordjournals.eurheartj.a059936","article-title":"Comparison of anti-platelet properties of molsidomine, isosorbide-5-mononitrate and placebo in healthy volunteers","volume":"12","author":"Drummer","year":"1997","journal-title":"Eur. Heart J."},{"issue":"12","key":"10.1016\/j.bcp.2019.05.030_b0760","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1016\/j.jacc.2006.10.074","article-title":"Once daily therapy with isosorbide-5-mononitrate causes endothelial dysfunction in humans: evidence of a free-radical-mediated mechanism","volume":"49","author":"Thomas","year":"2007","journal-title":"J. Am. Coll. Cardiol."},{"issue":"11","key":"10.1016\/j.bcp.2019.05.030_b0765","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/clc.4960231110","article-title":"Isosorbide dinitrate inhibits platelet adhesion and aggregation in nonthrombolyzed patients with acute myocardial infarction","volume":"23","author":"Gebalska","year":"2000","journal-title":"Clin. Cardiol."},{"issue":"2","key":"10.1016\/j.bcp.2019.05.030_b0770","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1053\/gast.2000.9304","article-title":"Nitric oxide in mucosal defense: a little goes a long way","volume":"119","author":"Wallace","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bcp.2019.05.030_b0775","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1053\/j.gastro.2004.07.048","article-title":"Risk assessment of endogenous formation of carcinogenic N-nitroso compounds in response to intake of NO-Aspirin","volume":"127","author":"Kleinjans","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bcp.2019.05.030_b0780","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/0304-3835(95)03786-V","article-title":"Role of N-nitroso compounds (NOC) and N-nitrosation in etiology of gastric, esophageal, nasopharyngeal and bladder cancer and contribution to cancer of known exposures to NOC","volume":"93","author":"Mirvish","year":"1995","journal-title":"Cancer Lett."},{"issue":"2","key":"10.1016\/j.bcp.2019.05.030_b0785","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/j.1527-3466.2006.00148.x","article-title":"Pharmacologic profile and therapeutic potential of NCX 4016, a nitric oxide-releasing aspirin, for cardiovascular disorders","volume":"24","author":"Gresele","year":"2006","journal-title":"Cardiovasc. Drug Rev."},{"issue":"3","key":"10.1016\/j.bcp.2019.05.030_b0790","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1124\/jpet.105.089896","article-title":"Direct and irreversible inhibition of cyclooxygenase-1 by nitroaspirin (NCX 4016)","volume":"315","author":"Corazzi","year":"2005","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"4","key":"10.1016\/j.bcp.2019.05.030_b0795","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.bbrc.2003.10.079","article-title":"Effect of nitric oxide-donating agents on human monocyte cyclooxygenase-2","volume":"311","author":"Corazzi","year":"2003","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"5","key":"10.1016\/j.bcp.2019.05.030_b0800","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1055\/s-0038-1650662","article-title":"The antiplatelet effects of a new nitroderivative of acetylsalicylic acid - an in vitro study of inhibition on the early phase of platelet activation and on TXA2 production","volume":"76","author":"Zuliani","year":"1996","journal-title":"Thromb. Haemost."},{"issue":"7","key":"10.1016\/j.bcp.2019.05.030_b0805","doi-asserted-by":"crossref","first-page":"4202","DOI":"10.1073\/pnas.071054698","article-title":"Role of the arginine-nitric oxide pathway in the regulation of vascular smooth muscle cell proliferation","volume":"98","author":"Ignarro","year":"2001","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"8","key":"10.1016\/j.bcp.2019.05.030_b0810","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1038\/sj.bjp.0704209","article-title":"Vasorelaxant effects of a nitric oxide-releasing aspirin derivative in normotensive and hypertensive rats","volume":"133","author":"Muscar\u00e1","year":"2001","journal-title":"Br. J. Pharmacol."},{"issue":"3","key":"10.1016\/j.bcp.2019.05.030_b0815","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1160\/TH04-07-0464","article-title":"Nitroaspirin plus clopidogrel versus aspirin plus clopidogrel against platelet thromboembolism and intimal thickening in mice","volume":"93","author":"Momi","year":"2005","journal-title":"Thromb. Haemost."},{"issue":"1","key":"10.1016\/j.bcp.2019.05.030_b0820","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0014-2999(00)00223-5","article-title":"Prevention of pulmonary thromboembolism by NCX 4016, a nitric oxide-releasing aspirin","volume":"397","author":"Momi","year":"2000","journal-title":"Eur. J. Pharmacol."},{"issue":"3","key":"10.1016\/j.bcp.2019.05.030_b0825","first-page":"349","article-title":"Antiplatelet agents in clinical practice and their haemorrhagic risk","volume":"11","author":"Gresele","year":"2013","journal-title":"Blood Transfus."},{"issue":"3","key":"10.1016\/j.bcp.2019.05.030_b0830","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1073\/pnas.022639399","article-title":"Efficacy and age-related effects of nitric oxide-releasing aspirin on experimental restenosis","volume":"99","author":"Napoli","year":"2002","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"3","key":"10.1016\/j.bcp.2019.05.030_b0835","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1160\/TH06-10-0555","article-title":"Prevention by NCX 4016, a nitric oxide-donating aspirin, but not by aspirin, of the acute endothelial dysfunction induced by exercise in patients with intermittent claudication","volume":"97","author":"Gresele","year":"2007","journal-title":"Thromb. Haemost."},{"issue":"6","key":"10.1016\/j.bcp.2019.05.030_b0840","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.2337\/dc09-2013","article-title":"Hyperglycemia-induced platelet activation in type 2 diabetes is resistant to aspirin but not to a nitric oxide-donating agent","volume":"33","author":"Gresele","year":"2010","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.bcp.2019.05.030_b0845","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1016\/j.jvs.2012.05.064","article-title":"Effect on walking distance and atherosclerosis progression of a nitric oxide-donating agent in intermittent claudication","volume":"56","author":"Gresele","year":"2012","journal-title":"J. Vasc. Surg."},{"issue":"22","key":"10.1016\/j.bcp.2019.05.030_b0850","doi-asserted-by":"crossref","first-page":"8497","DOI":"10.1073\/pnas.0401996101","article-title":"Nitric oxide (NO)-releasing statin derivatives, a class of drugs showing enhanced antiproliferative and antiinflammatory properties","volume":"101","author":"Ongini","year":"2004","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"11","key":"10.1016\/j.bcp.2019.05.030_b0855","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1111\/j.1538-7836.2005.01605.x","article-title":"A novel nitric oxide-releasing statin derivative exerts an antiplatelet\/antithrombotic activity and inhibits tissue factor expression","volume":"3","author":"Rossiello","year":"2005","journal-title":"J. Thromb. Haemost."},{"issue":"3","key":"10.1016\/j.bcp.2019.05.030_b0860","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1093\/cvr\/cvs100","article-title":"Nitric oxide enhances the anti-inflammatory and anti-atherogenic activity of atorvastatin in a mouse model of accelerated atherosclerosis","volume":"94","author":"Momi","year":"2012","journal-title":"Cardiovasc. Res."},{"issue":"7","key":"10.1016\/j.bcp.2019.05.030_b0865","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/sj.bjp.0707142","article-title":"Nitropravastatin stimulates reparative neovascularisation and improves recovery from limb ischaemia in type-1 diabetic mice","volume":"150","author":"Emanueli","year":"2007","journal-title":"Br. J. Pharmacol."},{"issue":"2","key":"10.1016\/j.bcp.2019.05.030_b0870","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1527-3466.2005.tb00162.x","article-title":"Preclinical profile of PF9404C, a nitric oxide donor with \u03b2 receptor blocking properties","volume":"23","author":"Villarroya","year":"2006","journal-title":"Cardiovasc. Drug Rev."},{"issue":"14","key":"10.1016\/j.bcp.2019.05.030_b0875","doi-asserted-by":"crossref","first-page":"3947","DOI":"10.1016\/j.bmc.2018.06.017","article-title":"Design, synthesis and biological evaluation of nitric oxide releasing derivatives of dapagliflozin as potential anti-diabetic and anti-thrombotic agents","volume":"26","author":"Li","year":"2018","journal-title":"Bioorg. Med. Chem."},{"issue":"11","key":"10.1016\/j.bcp.2019.05.030_b0880","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1016\/j.bmcl.2017.04.007","article-title":"Synthesis antiplatelet and antithrombotic activities of resveratrol derivatives with NO-donor properties","volume":"27","author":"Dutra","year":"2017","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"4","key":"10.1016\/j.bcp.2019.05.030_b0885","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1111\/jcmm.14191","article-title":"Cardioprotective effect of MMP-2-inhibitor-NO-donor hybrid against ischaemia\/reperfusion injury","volume":"23","author":"Krzywonos-Zawadzka","year":"2019","journal-title":"J. Cell. Mol. Med."},{"issue":"11","key":"10.1016\/j.bcp.2019.05.030_b0890","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1111\/j.1538-7836.2005.01614.x","article-title":"Intraplatelet signaling mechanisms of the priming effect of matrix metalloproteinase-2 on platelet aggregation","volume":"3","author":"Falcinelli","year":"2005","journal-title":"J. Thromb. Haemost."},{"issue":"7","key":"10.1016\/j.bcp.2019.05.030_b0895","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1182\/blood-2016-06-724245","article-title":"A novel mechanism regulating human platelet activation by MMP-2\u2013mediated PAR1 biased signaling","volume":"129","author":"Sebastiano","year":"2017","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.bcp.2019.05.030_b0900","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.tips.2008.05.002","article-title":"Potentiation and priming of platelet activation: a potential target for antiplatelet therapy","volume":"29","author":"Gresele","year":"2008","journal-title":"Trends Pharmacol. Sci."},{"issue":"19","key":"10.1016\/j.bcp.2019.05.030_b0905","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1161\/01.CIR.103.19.2371","article-title":"L-arginine and S-nitrosoglutathione reduce embolization in humans","volume":"103","author":"Kaposzta","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.bcp.2019.05.030_b0910","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/S0022-3565(24)29549-5","article-title":"The nitroderivative of aspirin, NCX 4016, reduces infarct size caused by myocardial ischemia-reperfusion in the anesthetized rat","volume":"297","author":"Rossoni","year":"2001","journal-title":"J. Pharmacol. Exp. Ther."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295219302187?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295219302187?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T13:05:15Z","timestamp":1757768715000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295219302187"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":182,"alternative-id":["S0006295219302187"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2019.05.030","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nitric oxide-enhancing or -releasing agents as antithrombotic drugs","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2019.05.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}